Latest Insider Transactions at Hologic Inc (HOLX)
This section provides a real-time view of insider transactions for Hologic Inc (HOLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HOLOGIC INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HOLOGIC INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2024
|
Karleen Marie Oberton Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
52,679
-38.53%
|
$4,214,320
$80.56 P/Share
|
|
Aug 29
2024
|
Karleen Marie Oberton Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,805
+10.7%
|
$1,312,200
$40.91 P/Share
|
|
Aug 06
2024
|
Brandon Schnittker Div. President, GYN Surgical |
SELL
Open market or private sale
|
Direct |
476
-11.3%
|
$39,508
$83.11 P/Share
|
|
Aug 01
2024
|
Benjamin Jordan Cohn Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,093
-32.71%
|
$412,533
$81.99 P/Share
|
|
Jul 30
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
44,039
-1.24%
|
$3,567,159
$81.45 P/Share
|
|
Jul 30
2024
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,039
+3.54%
|
$1,145,014
$26.21 P/Share
|
|
Jul 17
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
3,672
-0.32%
|
$293,760
$80.13 P/Share
|
|
Jul 17
2024
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,672
+0.32%
|
$95,472
$26.21 P/Share
|
|
Jul 17
2024
|
Christiana Stamoulis Director |
SELL
Open market or private sale
|
Direct |
9,039
-16.58%
|
$714,081
$79.5 P/Share
|
|
Jul 17
2024
|
Christiana Stamoulis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,039
+14.22%
|
$235,014
$26.74 P/Share
|
|
May 31
2024
|
Brandon Schnittker Div. President, GYN Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
67
-1.57%
|
$4,891
$73.78 P/Share
|
|
May 23
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
57,875
-4.76%
|
-
|
|
Apr 22
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
12,000
-0.98%
|
-
|
|
Apr 19
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
12,000
-0.97%
|
-
|
|
Mar 14
2024
|
Scott T Garrett Director |
SELL
Open market or private sale
|
Direct |
16,441
-25.27%
|
$1,233,075
$75.5 P/Share
|
|
Mar 14
2024
|
Scott T Garrett Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,441
+11.89%
|
$509,671
$31.39 P/Share
|
|
Mar 08
2024
|
Charles J Dockendorff Director |
SELL
Open market or private sale
|
Direct |
1,465
-48.24%
|
$111,340
$76.21 P/Share
|
|
Mar 08
2024
|
Sally Crawford Director |
SELL
Open market or private sale
|
Direct |
9,039
-6.37%
|
$686,964
$76.4 P/Share
|
|
Mar 08
2024
|
Sally Crawford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,039
+5.99%
|
$235,014
$26.74 P/Share
|
|
Mar 07
2024
|
Charles J Dockendorff Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+34.11%
|
-
|
|
Mar 07
2024
|
Sally Crawford Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+1.17%
|
-
|
|
Mar 07
2024
|
Amy Mc Bride Wendell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+7.05%
|
-
|
|
Mar 07
2024
|
Stacey D. Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+32.24%
|
-
|
|
Mar 07
2024
|
Nanaz Mohtashami Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+40.42%
|
-
|
|
Mar 07
2024
|
Christiana Stamoulis Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+3.34%
|
-
|
|
Mar 07
2024
|
Scott T Garrett Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+3.13%
|
-
|
|
Mar 07
2024
|
Ludwig Hantson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+12.41%
|
-
|
|
Jan 29
2024
|
Karleen Marie Oberton Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,940
-12.57%
|
$1,120,500
$75.0 P/Share
|
|
Jan 02
2024
|
Charles J Dockendorff Director |
SELL
Open market or private sale
|
Direct |
16,017
-91.62%
|
$1,153,224
$72.0 P/Share
|
|
Jan 02
2024
|
Charles J Dockendorff Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,551
+30.16%
|
$286,938
$38.44 P/Share
|
|
Dec 13
2023
|
Peter Paul Dunne SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
1,231
+10.37%
|
-
|
|
Dec 11
2023
|
Scott T Garrett Director |
SELL
Open market or private sale
|
Direct |
10,000
-17.53%
|
$680,000
$68.71 P/Share
|
|
Nov 29
2023
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
47,711
-3.71%
|
$3,339,770
$70.41 P/Share
|
|
Nov 29
2023
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,711
+3.58%
|
$1,240,486
$26.21 P/Share
|
|
Nov 21
2023
|
Essex D Mitchell Div. President, GYN Surgical |
SELL
Open market or private sale
|
Direct |
7,500
-36.9%
|
$532,500
$71.85 P/Share
|
|
Nov 14
2023
|
Karleen Marie Oberton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,687
+6.81%
|
-
|
|
Nov 14
2023
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,832
+3.19%
|
-
|
|
Nov 14
2023
|
Essex D Mitchell Div. President, GYN Surgical |
BUY
Grant, award, or other acquisition
|
Direct |
8,687
+29.94%
|
-
|
|
Nov 14
2023
|
Jennifer M Schneiders President, Diag. Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
3,475
+35.42%
|
-
|
|
Nov 14
2023
|
Jan Verstreken Group President, International |
BUY
Grant, award, or other acquisition
|
Direct |
6,950
+7.49%
|
-
|
|
Nov 14
2023
|
Benjamin Jordan Cohn Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,216
+7.4%
|
-
|
|
Nov 14
2023
|
John M. Griffin General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,950
+4.01%
|
-
|
|
Nov 14
2023
|
Elisabeth A Hellmann SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
1,390
+12.68%
|
-
|
|
Nov 14
2023
|
Erik S Anderson Div. Pres., Breast & Skeletal |
BUY
Grant, award, or other acquisition
|
Direct |
3,822
+18.82%
|
-
|
|
Nov 09
2023
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
65,811
-5.21%
|
$4,409,337
$67.2 P/Share
|
|
Nov 09
2023
|
Jan Verstreken Group President, International |
SELL
Payment of exercise price or tax liability
|
Direct |
1,478
-1.84%
|
$99,026
$67.2 P/Share
|
|
Nov 09
2023
|
Karleen Marie Oberton Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,899
-9.0%
|
$730,233
$67.2 P/Share
|
|
Nov 09
2023
|
Essex D Mitchell Div. President, GYN Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
2,300
-16.5%
|
$154,100
$67.2 P/Share
|
|
Nov 09
2023
|
Jennifer M Schneiders President, Diag. Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-5.73%
|
$11,658
$67.2 P/Share
|
|
Nov 09
2023
|
John M. Griffin General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,375
-5.55%
|
$628,125
$67.2 P/Share
|